MediPharm Labs Corp., a pharmaceutical company specialized in precision-based cannabinoids, announced that David Pidduck will be stepping down from his role as the Company’s Chief Executive Officer, effective January 23rd, 2026. The Board of Directors (the “Board”) has appointed Greg Hunter, the Company’s Chief Financial Officer, as Interim Chief Executive Officer, while it evaluates its long‑term leadership plans. Mr. Hunter will continue to serve as Chief Financial Officer during this interim period.
Mr. Pidduck has played a critical role in stabilizing and repositioning the Company. Under his leadership, MediPharm successfully executed significant restructuring initiatives, improved profitability, and completed the transformative integration of VIVO Cannabis Inc. following its acquisition by the Company in April 2023. Mr. Pidduck will continue to serve on the Board to ensure a seamless transition.
The Board is pleased to appoint Mr. Hunter as Interim Chief Executive Officer. Since assuming the Chief Financial Officer role in February 2021, he has implemented meaningful cost‑reduction initiatives and strengthened financial and operational controls. He has also been deeply involved in commercial strategy, working closely with the sales, marketing, and product teams to enhance pricing, support key customer programs, negotiate improved commercial terms, and ensure manufacturing and supply capabilities align with market demand. His cross‑functional leadership has contributed to stronger execution, improved margins, and a more competitive commercial position.
In addition to his financial background, Mr. Hunter also brings broad commercial, operational, and general management experience, gained over more than 20 years in cross-functional leadership roles at global Fortune 500 organizations such as Johnson & Johnson and Baxter, as well as private equity portfolio companies. With his extensive multi-disciplinary experience, spanning finance, sales, marketing, and operations, Mr. Hunter is well positioned to advance MediPharm’s strategic priorities.
Chris Taves, Chair of the Board, commented: “On behalf of the Board and the entire MediPharm Labs team, I want to thank David for his significant contributions. His leadership played a key role in strengthening MediPharm’s financial trajectory and guiding the Company through challenging market conditions. We are equally pleased to have a seasoned leader like Greg step into the Interim CEO role during this transition and the Board is confident in his ability to drive execution, operational discipline, and focused growth in the months ahead.”
